Skip to Content



Genomic Sequencing Technology Has Become Indispensable

December 18, 2019 21:30 PM UTC
- Updated February 18, 2020 16:09 PM UTC

Leaders and investors in sequencing technology share the latest developments and breakthroughs in the space, and discuss the implications for humanity–and business.

I don't want to talk. Uh, you mentioned this idea of the genomic revolution, which were, You know, we've been talking about for a while, but we're now in actually a revolution of revolution. There's so much happening. It's not just that we've got faster and cheaper, radically faster and deeper gene sequencing technology in the next generation of that. But in addition, we have ah, whole new set of gene editing tools that are radically changing science, the ability to actually intervene in our own DNA. We have, in addition of that, the revolution in a I and deep learning, which we've been hearing about, which is giving us a brand new molecular genetic targets of extraordinary complexity that we never even dreamed of pursuing before we have a revolution immuno oncology, which is helping us understand how to harness the immune system to fight things like cancer. And we've already talked about the revolution's inside G and mobility and sensors and everything else in robotics. So my question for you Simone to start with is, Is this time different? Are we really in a place where this confluence of revolutions is different than it ever has been before? and if so, how on earth do you start to invest in that? I think the president revolution is definitely here. It's a revolution off a combination of revolution off biology and, um, the machine learning the eye. The example, If you want to go for if we want to go for cancer, early detection is almost a dream, but it is a combination of understanding the genomic features, an accompaniment and also the ability to deep sequencing by using air tours. Yeah, so you know, just a follow up, though you know, when there's so many new technologies, how do you make the bet that you know that harness all of them together? Or do you focus on very specific kinds of attacked because your investments are really unique? As I've been looking Thio, I think only in my experience, I think that formula only applies to venture capital investments or venture investors who intend to investing company at a very early stage. So to be successful. Actually, the principle is not to invent, not to diversify. Actually, it's a concentrating to concentrating areas where you can understand the technology or you have the ability to assemble resources that can help you capture the most advanced technology. So the key is not to not to dance with the central life is to focus. That's interesting. That's interesting. Leeching I wantto mention this other revolution, which I didn't mention include that which is the consumer revolution. And you know so much of the growth in your business making these extraordinary gene sequencing devices. There has been a movement towards things like 23 me and ancestry dot com and color and garden and several others, you know, But But recently over the summer, there was some softness in that market and that affected your stock and, you know, it's still sort of hasn't quite recovered. The question is, is that a temporary setback? Are we gonna still see the consumer market dominate in the next day year? Okay, so I see most audience Chinese. Can I speaking Chinese? Yeah. Please. Uh, why are you doing with that? You see, for the aluminum technology in us, they have Mad Jean Company that 23 me, as you mentioned on the hotel companies are using JI and technologies during their set up. They use the genomics, do not make analysis because, uh, US is composed of different races, so race analysis is a key topic. But after all the population being analyzed by the races for the man do not make companies that they are declining in their business. So all these companies are trying very hard to explore the new areas, for example, Jeanne's impact to the human health to their lifestyles on also to the nutrition. Next bet Some gene companies were even dedicated to the education off the infants on also babies and Children. So they were doing explorations. As soon as they identify the new areas, definitely they're going to be promising futures in those areas in China, situations that are slightly different. Large majority afternoon companies are still you since infancy, period like a 23 magic box on other companies that they have a very good application. Situations s allowed to continue the investment, and still, you try rapid developments into this in a big way. I mean, you've got the UK, for example, which is sequencing 450,000 people. You've got the in the U. S. You've got all of us, uh, you know, program at the N I. H. with just two million. And then you just signed a deal with in China, right to do something similar to that woman's union. Just woman. Indeed, last year with, except for Lee won a bead, it was a tendering process is in the Harbin Hospital University on Dhe. It was a joint project by the Minister of Health on the most the minister of Science and technology. They selected Theo, the our company, to conduct the population. Cho heard a study. This is very conducive on beneficial to accumulate wth e big green data for China on DDE. With this data bases, it's very conducive to study the treatment technologies. I'm very happy that the Harbin University, on also most on the ministry off houses, selected our technology. We are going to learn the statistics from UK and us as well as those cutting edge technologies in the inflammation had not refute, you know, cold, hard to study. You know, one of the things that Ching mentioned is that drug companies are using this genetic profiling, understand how drugs work. There's another revolution happening right here in China. There, 15 1000 drugs in the drug development pipeline here and obviously GPC is the China's largest producer and a distributor of drugs, including traditional Chinese medicines. Are you? What are you doing to make sure that there are new technologies that are finding new biological targets for those kinds of drugs? And could you talk a little bit about the effort to create international standards for some of these Chinese traditional medicine? Just No. Mr Lee mentioned a lot about the about logical technologies breakthroughs in the prevention, diagnosis, even the treatment off the issue, even the culture tissue culture applications. We know a lot about logical technologies that since 19 seventies, after four decades, the involvement remarkable progress is on milestones being made. A. A lot of new products provide to the humankind to improve the well being off the humans in China. In the full commercialization I industrialization Alva gene technology. But it's, ah, gradual protests. Our group, as the Large is the leading pharmaceutical company in China. We runk number one for consecutive eight years. In recent years, we focus on the biological drugs RND work, especially the whole value chain. In particular, the supporting services in the whole value chain, including the dog knows, is by using biological technologies on also the biological treatment. We had a lot of strength and advantages, but in rolling out those technologies, we have one gene drug to cure the 10% incidence. Uh, habitants is diseases in China. Hepatitis is a beat, but the review and approval process in China because there's a new ad, a crater guideline in China, available So our work progress. They're very slowly but in the process, the cutting edge technology like a from Illumina on the other companies. This would definitely promote the rules on regulation. Drafting by the city in China revealed center off the drug. So we look forward to that. Just get into this idea of a I and using artificial intelligence. You know, in all of these intersections that we're talking about and, you know, particularly in the case of cancer and you last year on this stage you said that eight. That the chance or sell is the perfect, eh? I sell and I love that you said, You know, it grows faster, it evolves faster. It thinks faster, innovating, fact detection faster at essentially it is a, you know, a super artist, super intelligence cell, and yet you and you're also using the same kind of technologies to outwit that any I sell. So I think, to combat cancer, right? The most relevant factor, actually is too be able to detect cancer early in 12 more forms before one him too much. It has about one billion cells, and it has ordered a outsell features so much difficult to defeat. 10. So once it's there. So the best that the Revolution of Breakthrough in cancer treatment actually is to detect cancer faster earlier. And given that Illumina has done its job by giving us all sorts of sequencing, sequencing tours, different size, different throughput access so that part of the leg off the Revolution's already in terms of early cancer detection, the the rest is up to the industry to come up with the simple preparation tours in order for this whole game to happen. So Clint Quater earlier talked about a number of companies. When we talk about sequencing cancer related, see Quincy, a lot of names come to pop up. For example, 23 me will foundation medicine got in health, so I like to take this opportunity to clarify a bit. 23 army is for fun, a lot of fun because it gives you the A give you the genetic feature as to who you are, what your family tree is. And it tells you genetically what kind of health risks you might be exposed to. But it is not intend for any diagnosis. It is not to be able to detect cancer. Definitely not for $99 it won't even give you a deep, uh, give you a whole genome sequencing picture unless, uh, Lumina achieves another revolution driving around the park. You know, bye bye by 10 votes, for example. But Ching is already in fact, we were talking earlier. And if you go from the cost of sequencing an entire genome 20 years ago, three amending Thio about $1000 where you're pretty close to that now in terms of liquid biopsies. So this is what you were referring to. The ability to detected telltale fragments of DNA, tiny little fragments of DNA and use that to bio markers of a disease progression. You spun off a company alumina called Grail, to do just that. And there have been a number of these liquid biopsy companies. How how good are they in terms of identifying disease progression? Similar says, You know, we've got to get earlier in the intervene earlier in that disease. I think that grill is You know, I'm very, very glad that alumina help produce a company called the Grill Grill. 23 Minutes for Fun Grill is a Dream is a beautiful dream, intends to detect cancer at a very early stage to substantially increase survival rate. What it does is it get a noble blood from you and then try to capture the DNA and I in a release from tumor cell into the blood so it is relevant from sign for interview. But the difficulty is that the difficulty or the challenges that it won't be able to tell you or reflect the genomex feature from the tumors from which they originated. So I might be able to tell you you may have cancer, but I don't know what kind of cancer it is and how it comes is how it managed to come to you. But I felt, but with a green riel, we don't even dare to dream. So Grill is a beautiful dream, but I think there is hope the hope is another company for the strike. Strife is backed by very the mission. All off, life is the same as Brill. But the difference is, I think, is that Allow me to say that we were No, I'm not being disrespectful to grill. I think we've established a torch, which is really important. But Charlotte is back to buy very solid signs. The the Johns Hopkins team, through decades of research in 2018 has put out a beautiful paper in signs a test. It is able to localize the mutated, uh, cancel. Basically in nails down from hundreds, hundreds, thousands off the unknown man numbers of the mutations, it is able to nail it down. 61 cancer related hot spots. Mutation with that 61 someone might. So I want to come back and sing just a second, but I want to see if anyone has a question out there. And if you do, we've got some Mike Wranglers and we'll have a paddle up there. Anybody have a question? Okay. Uh, well, if you do just a second. I'll come right back to you. Ching, We talked about this idea of using a I though, to be able to make a little bit more sense to ask those impossible questions, if you will, about what gene interactions are most likely to cause disease later on. Whether it's a miss sense mutation or a delusion or a specific nuclear tied or whatever it is, we know that in some cases, some some mutations are more important than others. And can you talk a little bit about what alumina, How alumina is filling that gap? Yeah. Um uh, It is like this alumina. The way we feel, the garb, it's different. We ourselves a lot of R and D off different diseases on diagnostics, off meth er's. However, we pay more attention. We will have Maura opening our technological plant for to engage many companies, our platform toe study to research diagnostic of diseases, the Beautician Models and mechanism, for example, in China right now, all in tumor way burning rock In the we work was done microbiology and belongs over. Also partner with teaching you are my new project Alumina. We alter our plan for not we ourselves using I tool to explore the diagnostic off. This is rather we open up our system all the I Already darkness is interested. Companies work on our platform to do their R and d. So the development resolved. Indeed, is changing every day, basically globally in China, every day we have paper coming out to see the dark. Most of our money disease is marching, making progress. So in this way are very unique company relying on equal system to get the solutions for human diseases. Diagnostics, machines and tools are used in 90% of the world's sequencing. So it's kind of an amazing figure. How you have you managed to capture that entire market there? Let's see if we have a question from the audience. Anybody? Yeah, we got one right there. Martin Rees. I identified you, but you must will identify yourself again. Yeah, Martin Reeves from the BCG Henderson Institute. I want you to ask Thes technologies have profound, profound functionality. Of course, one of the problems with pharmaceutical researchers stagnant productivity, valuable drugs per dollar or unit of effort. Have we reached the point yet where these technologies are impacting on that stagnating rd productivity? Anybody? Yeah. Simone, You wanna take that? Our madam? Yeah. Yeah, if I may. Yes. I think sequencing that has a clinical application either to test cancer Patients will go for early detection, but sequencing is also very, very relevant in basic research. For example, a company called a Foundation medicine, it has a box of 500 genes. It really is very relevant in enabling research to want to identify a new mechanism. But how to make it a clinical relevance toward to link towards your new attention to what disease? I think, uh, Jean Jean, all the technology has come to a point where it is very amiable into basic research or clinical research. We have one more question. Time for one more question. Anybody light, son? Yeah. Anybody I thought I saw another hand. Somebody shy out there. Doesn't want to ask you a question. All right. So you want I've got a question for you on again, getting into the idea with so much, you know, histories of science in the Chinese drug development world. Yet there isn't that much. There aren't that many Chinese made drugs that are actually being sold overseas and markets overseas. How are you beginning to change that? We saw one approval on FDA approval for a new Alzheimer's drug just the other day. But this is this is it needs to be a paradigm shift for China to enter the world of innovative farmers. Thank you very much for your question. So I was smart. This disease is a important. It's become more, more, uh, everybody's challenged by the island hammers. So traditional charges medicine 55 years off for you is very employed. A very important role for the involvement. Progress off Chinese societies, traditional medicine. So it has its uniqueness in treating the sick. So my company has been dedicated to rd off this kindof traditional medicines. Right now, one off the trucks we did. We have complete all the clinical work for early stage mid stage Alzheimer's has very the efficacy is very good bye internationally, we don't know have a appraisal, the evaluation standard criteria. So those big So this product has been placed in the draw Appraisal central. Actually, our product this product iss even better, more efficient than they just approved by the government medicine treating Alzheimer's. It's better. However, we still want to make more effort to promote the mechanization. The market longs off this rock so we can have a very good efficacy. So this traditional kind serve it bigger segment of the population. It is not believed traditional Madison, in curing preventing humankind, will play a bigger role. Much. We're gonna have to leave it there. Thank you, madam. You teaching and Simone song? I appreciate that.